NASDAQ: MTSRMetsera Inc Stock
$19.51-0.06 (-0.31%)
Updated Apr 21, 2025
MTSR Price
$19.51
Fair Value Price
$4.48
Market Cap
$2.05B
52 Week Low
$12.30
52 Week High
$32.81
P/E
-1.35x
P/B
-8.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$209.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.65
Operating Cash Flow
-$100M
Beta
1.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MTSR Overview
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MTSR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MTSR
Ranked#262 of 462
Ranked#262 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important MTSR news, forecast changes, insider trades & much more!
MTSR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MTSR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTSR ($19.51) is overvalued by 335.53% relative to our estimate of its Fair Value price of $4.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MTSR ($19.51) is not significantly undervalued (335.53%) relative to our estimate of its Fair Value price of $4.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MTSR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MTSR due diligence checks available for Premium users.
Valuation
MTSR fair value
Fair Value of MTSR stock based on Discounted Cash Flow (DCF)
Price
$19.51
Fair Value
$4.48
Overvalued by
335.53%
MTSR ($19.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MTSR ($19.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MTSR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MTSR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.35x
Industry
-184.27x
Market
27.14x
MTSR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.08x
Industry
4.04x
MTSR's financial health
Profit margin
Revenue
$0.0
Net Income
-$52.9M
Profit Margin
0%
MTSR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$451.0M
Liabilities
$163.6M
Debt to equity
-0.65
MTSR's short-term assets ($359.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTSR's short-term assets ($359.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTSR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MTSR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$36.4M
Investing
-$1.0k
Financing
$202.2M
MTSR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTSR vs Biotech Stocks
Metsera Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.